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A B S T R A C T   
A2B adenosine receptors are present in a wide spectrum of tissues, especially on cells of the immune system. Since 
these particular receptors have the lowest, of all adenosine receptor subtypes, affinity for adenosine they are 
believed to play a special role in immunological processes associated with elevated adenosine levels such as 
inflammation. 
The aim of this preliminary study was to determine the potential anti-inflammatory properties of compound 
PSB-603, a potent and selective adenosine A2B receptor antagonist, in two different experimental models of local 
and systemic inflammation. 
In a model of inflammation induced by local carrageenan administration paw edema was measured using a 
pletysmometer. Additionally, levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha 
(TNF-α) and reactive oxygen species (ROS) were determined in the inflamed paw. Using the mouse model of 
peripheral inflammation induced by intraperitoneal (ip) administration of zymosan A, the influence of the A2B 
antagonist on the infiltration of neutrophils into the peritoneum and its effect on the plasma levels of CRP, TNF-α, 
and IL-6 were investigated. 
The results showed that PSB-603 administered at a dose of 5 mg/kg b.w. ip significantly reduced inflammation 
in both tested models. Particularly, it significantly decreased levels of the inflammatory cytokines IL-6, TNF-α 
and of ROS in the inflamed paw and reduced inflammation of the peritoneum by significantly decreasing the 
infiltration of leukocytes. Additionally, in the latter model, no statistically significant difference was observed in 
the CRP level between the control group without inflammation and the group which has been treated with the 
PSB-603 compound. Thus, the results may indicate the anti-inflammatory activity of adenosine A2B receptor 
antagonists in two different models of inflammation.   
1. Introduction 
Inflammation is defined as one of the defence mechanisms against 
external factors interfering with the body’s natural homeostasis. It is 
associated with unpleasant feelings, often causes suffering, and it might 
lead to the state of severe, life-threatening disorders [1]. Inflammation is 
observed in the course of various pathological conditions e.g. infection, 
trauma, acute ischemia, burns, poisoning or obesity and it is considered 
to be a hallmark of many important diseases such as cardiovascular, 
metabolic, intestinal and pulmonary disorders [2–6]. Regardless of the 
cause, the same mediators are involved in all inflammatory responses, 
and their systemic effects lead to similar disorders. The search for new 
anti-inflammatory drugs is therefore extremely important considering 
the wide group of patients struggling with inflammation and its 
consequences. 
In recent years adenosine has been considered to be one of the most 
important mediators and modulators of the immune system response. 
There are four known subtypes of adenosine receptors namely A1, A2A, 
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A2B and A3 [6]. All of them belong to the group of cell surface receptors 
called GPCRs (G-protein-coupled receptors). These receptors, activated 
by extracellular adenosine, are present on almost all immune cells and 
via its action adenosine may modulate various aspects of both immune 
and inflammatory responses. As to the regulation of immune activity 
adenosine effects are mostly anti-inflammatory and are mainly 
concentrated on the tissue protection [7]. 
Adenosine receptors have different affinity to its ligand and thus they 
are activated at the different adenosine concentrations. Receptor A2B is 
the one with the lowest affinity to adenosine (μM concentrations) 
therefore it mostly remains silent, since under resting conditions aden-
osine levels are only between ten and few hundred nM [8]. The affinities 
of other adenosine receptor subtypes are much higher, which makes 
them active at significantly lower adenosine concentrations. However, 
in pathophysiological conditions when adenosine concentrations are the 
highest, the role of A2B receptor becomes more significant [9]. In such 
states actions mediated by A2B receptor signalling include, among 
others, reduction of the acute inflammation, increase of the ability of 
tissues to adapt to hypoxia, as well as increase of tolerance to ischemia 
under conditions of an acute insult. Long-term elevated adenosine levels 
and prolonged A2B receptor signalling are characteristic of a number of 
chronic diseases, ex.: inflammatory and fibrotic lung diseases (idio-
pathic pulmonary fibrosis, chronic obstructive pulmonary disease), 
asthma, bronchiolitis obliterans, pulmonary hypertension, sickle cell 
disease, cardiac remodelling after myocardial infarction, cancer 
(metastasis), chronic kidney disease and diabetes [6,10,11]. 
Therefore, we have decided to investigate the anti-inflammatory 
effect of compound PSB-603 – a known selective adenosine A2B recep-
tor antagonist, in two mice models of inflammation (local and systemic) 
and determine its antioxidant activity as well as effect on the levels of 
selected inflammatory cytokines. The specific models were selected 
based on our previous experience and after thorough study of the 
available literature on the subject [12–15]. The adenosine A2Breceptor 
antagonist chosen for this study displays greater than 17,000-fold 
selectivity over other adenosine receptor subtypes in humans (Kivalues 
are 0.553, >10,000, >10,000 and >10,000 nM for adenosine A2B, A1, 
A2Aand A3receptors, respectively) [16] and is similarly potent and se-
lective in rats and mice [17]. PSB-603 has been used in various studies as 
a standard antagonist for adenosine A2B receptors [18–21], but so far 
there are no reports of its activity in models of inflammation. 
2. Materials and methods 
2.1. Animals 
Adult male Albino Swiss mice, CD-1, weighing 25–30 g were used in 
this study. Animals were kept in environmentally controlled rooms, in 
standard cages lit by an artificial light for 12 h each day. Animals had 
free access to food and water, except for the time of the acute experi-
ment. The randomly established experimental groups consisted of 8 
mice. All animal care and experimental procedures were carried out in 
accordance with European Union and Polish legislation acts concerning 
animal experimentation, and were approved by the Local Ethics Com-
mittee at the Jagiellonian University in Cracow, Poland (Permissions No: 
256/2015, 55/2017). 
2.2. Drugs, chemical reagents and other materials 
Ketoprofen was used as a standard anti-inflammatory compound and 
was purchased from Sigma-Aldrich (Poland). Compound PSB-603 was 
synthesized at the PharmaCenter Bonn, Pharmaceutical Institute, Bonn, 
Germany as previously described [16] (Borrmann et al., 2009). Identity 
and purity of the final product was assessed by NMR and LC–MS 
techniques. 
2,2-Diphenyl-1-picrylhydrazyl and 2,4,6-tripyridyl-s-triazine were 
purchased from Sigma-Aldrich (Poland) and FeCl3⋅6H2O, ethanol, 
C2H3NaO2⋅3H2O, C2H4O2, HCl from POCH S.A. Gliwice (Poland). 
Carrageen was purchased from FCM Corporation (USA) and zymosan A 
from Sigma-Aldrich (Poland). 
2.3. In vitro methods 
2.3.1. In vitro antioxidant activity 
The antioxidant properties of PSB-603 compound were tested in vitro 
in two different assays: the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, 
and in the FeCl3 reduction activity assay (FRAP – ferric reducing anti-
oxidant power). 
2.3.1.1. DPPH assay. DPPH is a molecule containing a stable free 
radical. The reduction of DPPH in ethanol solution takes place in the 
presence of a hydrogen-donating antioxidant due to the formation of the 
non-radical form of DPPH-H. This transformation results in colour 
change from purple to yellow, which can be measured spectrophoto-
metrically. Discoloration of DPPH indicates the scavenging potential of a 
tested antioxidant. The investigated compound was tested at different 
concentrations ranging from 0.01 mM to 1 mM. To determine antioxi-
dant capacity, 5 μl of the PSB-603 solution (dissolved in 96 % ethanol) 
was mixed with 95 μl of 0.3 mM ethanolic DPPH solution. The change in 
the absorbance was detected at 517 nm after 30 min of incubation. 
Results were expressed as percent decrease in absorbance of the tested 
sample compared to the sample containing the solvent. L-Ascorbic acid 
was used as a reference compound. 
2.3.1.2. FRAP assay. A modified method of Benzie and Strain [22] was 
adopted for the FRAP assay [17]. The investigated compound was tested 
at different concentrations ranging from 0.01 mM to 1 mM. Readings of 
the coloured product (ferrous tripyridyltriazine complex) were taken at 
593 nm against ethanol. Results for the tested compound were expressed 
as an increase in absorbance of the tested sample compared to a sample 
containing the solvent. L-Ascorbic acid was used as a reference. 
2.4. In vivo methods 
2.4.1. Carrageenan-induced edema model 
To induce local inflammation, 0.1 mL of 1 % carrageenan solution in 
water was injected into the hind paw subplantar tissue of mice, ac-
cording to the modified method of C. A. Winter and P. Lence [23,24], as 
described previously [25]. The development of paw edema was 
measured with a plethysmometr (Plethysmometr 7140, Ugo Basile). 
Prior to the administration of the tested substances (PSB-603 or keto-
profen used as a reference standard), paw diameters were measured and 
recorded. The PSB-603 compound was administered at doses of 1, 5 or 
10 mg/kg b.w., intraperitoneally (ip), prior to carrageenan injection, 
similarly ketoprofen was administered at the dose of 5 mg/kg b.w. [26]. 
Both compounds were administered as suspensions in 1 % Tween 80, 
therefore 1 % Tween 80 (vehicle) was injected ip to the control group (it 
had no effect on edema, data not shown). Results were presented as 
changes in the hind paw volume registered 3 h after carrageenan 
administration. Immediately after paw volume measurement, mice were 
injected ip with heparin (2500 units/mice) and 20 min later the blood 
was collected from animals sacrificed by decapitation, and centrifuged 
at 600 × g (15 min, 4 ◦C) in order to obtain plasma for the quantification 
of C-reactive protein (CRP) levels. Then, the paws were isolated, placed 
in liquid nitrogen and stored at − 80 ◦C until biochemical tests were 
performed i.e. quantification of tumor necrosis factor alpha (TNF-α), 
interleukin-6 (IL-6) and reactive oxygen species (ROS). Samples were 
prepared by homogenization of 1 g of the tissue in 4 mL of 0.1 M 
phosphate buffer (pH 7.4) using an IKA-ULTRA-TURRAX T8 
homogenizer. 
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2.4.2. Zymosan A-induced peritoneal inflammation 
Peritoneal inflammation was induced as described previously [27]. 
Zymosan A solution was freshly prepared (2 mg/mL) in sterile 0.9 % 
NaCl and 30 min after ip injection of the investigated compounds 
(PSB-603 or ketoprofen, both at the dose of 5 mg/kg), zymosan A was 
injected via the same route. Both compounds were administered as 
suspensions in 1 % Tween 80, therefore 1 % Tween 80 (vehicle) was 
injected ip to the control group. Four hours later the animals were killed 
by decapitation. Mice plasma was collected in a heparin-containing 
tubes to determine the CRP, TNF-α and IL-6 levels. The peritoneal cav-
ity was lavaged with 1.5 mL of PBS and after 30 s of gentle manual 
massaging the exudates were retrieved. Cells were counted using an 
optical microscope (DM1000, Leica) and Bürker hemocytometer 
following staining with Turk’s solution. 
2.5. Biochemical analysis 
To determine IL-6 and TNF-α levels LANCE® Ultra Detection Kits 
(PerkinElmer, Inc, USA, catalogue numbers: TRF1505, TRF1504C/ 
TRF1504 M) were used. Standard enzymatic spectrophotometric tests 
(Shanghai Sunred Biological Technology Co., Ltd, China, catalogue 
number: 201-02-0219) were used for determination of CRP levels. 
Reactive oxygen species (ROS) were assayed using 2′,7′-dichloro-
fluorescein diacetate [28]. Calibration curve was prepared by dilution of 
10 μM ethanolic 2′7′-dichlorofluorescein stock solution. The highest 
calibration point equaled to 1 nM (0.4012 ng/mL). The subsequent 10 
calibration points were prepared by serial dilution of the highest con-
centration. Thus, the final calibration curve range was from 0 (pure 
solvent) to 0.4012 ng/mL. Fluorescence was monitored on a Spectro-
fluorimeter (Multiskan GO, Thermo Scientific), with excitation wave-
length at 488 nm and emission wavelength at 525 nm. 
2.6. Statistical analysis 
The results were analysed using a one-way variance analysis 
(ANOVA), followed by a Dunnett post-hoc test or by a Tukey post-hoc 
test, with the significance level set at 0.05. They were expressed as the 
means ± standard error of the mean (SEM), n = 8. Graph Pad Prism 6.0 
was used for data analysis. 
3. Result 
3.1. In vitro antioxidant activity 
Even at the highest concentration tested, in both in vitro assays, the 
investigated compound PSB-603 did not display any antioxidant activ-
ity. The results are presented in Fig. 1. 
3.2. Carrageenan-induced edema model 
Activity of the tested compound in the paw edema model was 
examined at three doses (1, 5 and 10 mg/kg b.w.). Ketoprofen at a dose 
of 5 mg/kg b.w. was used as a reference compound. In the control group 
(receiving 1 % Tween only) the mouse paw edema reached its peak at 3 
h after the carrageenan injection (increase by 97.7 % of the initial vol-
ume). As seen in Fig. 2A the increase in paw oedema was significantly 
inhibited in all groups receiving PSB-603. The dose of 5 mg/kg b.w 
turned out to be the most active and was chosen for further studies. In 
the plasma of mice treated with PSB-603 the decrease in CRP level 
however visible did not reach statistical significance (Fig. 2B). 
In the paw of mice treated with PSB-603, the TNF-α level was only 
slightly lower than in the control group with inflammation (Fig. 3A). 
However, the IL-6 level declined significantly and was comparable to the 
one observed in the ketoprofen treated group (Fig. 3B). Similarly, the 
level of ROS in the mice paw was significantly lower in the group treated 
with PSB-603 as compared to the control group (Fig. 3C). 
3.3. Zymosan A-induced peritoneal inflammation 
In the model of systemic inflammation, the early infiltration of 
neutrophils measured 4 h after zymosan-induced peritonitis was 
significantly inhibited in the group receiving PSB-603 vs untreated 
control group with inflammation, and results were comparable to the 
ones observed in the group receiving ketoprofen (Fig. 4A). CRP con-
centration in mice plasma was also slightly decreased in the group 
receiving PSB-603, however changes did not reach statistical signifi-
cance (Fig. 4B). TNF-α or IL-6 levels in plasma of mice treated with 
zymosan A and PSB-603 did not differ significantly from the levels in 
both control groups – with or without induced inflammation (Fig. 4C 
and D). In the group receiving ketoprofen, similarly to the results after 
PSB-603 administration, levels of CRP were virtually unchanged 
compared to the ones measured in the control group which was given 
zymosan A alone, however levels of IL-6 and TNF-α were significantly 
increased. 
4. Discussion 
The present study aimed to investigate whether a known, selective 
adenosine A2B adenosine receptor antagonist can exert positive, signif-
icant influence on inflammatory processes. In the literature, there is 
some data available on the benefits of using adenosine A2B receptor 
antagonists in inflammatory processes and their anti-inflammatory ac-
tivity [11,29–31], in addition to analgesic effects [32]. However, there is 
no information regarding this particular ligand [33,34], which is known 
to be a highly potent and selective adenosine A2B receptor antagonist in 
different species including humans and rodents commercially available, 
and used in various studies as a reference standard [17,20,21]. 
Fig. 1. Anti-oxidant in vitro test. 
Results are mean ± SEM, n = 6. Comparisons were performed by one-way 
ANOVA Dunnet’s post hoc. * - Significant against control. ***p < 0.001. 
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The first in vivo experiment performed was the carrageenan 
inflammation model. We have started administration of the tested 
compound PSB-603 at a dose of 10 mg/kg b.w., and because it was 
effective, subsequently lowered the dose first 2 times (5 mg/kg) and 
then 10 times (1 mg/kg), expecting to obtain logical loss of the effect. 
However, surprisingly the effect was stronger at the dose of 5 mg/kg b. 
w. than at 10 mg/kg b.w., and it decreased at 1 mg/kg. Therefore it was 
suspected that at the higher dose (10 mg/kg b.w.) PSB-603 might exert 
some pro-inflammatory activity. It is known that sometimes compound 
might act in a "U" dependence, and at both high and low doses, the 
expected effect disappears [35]. Moreover, in the spontaneous activity 
test the dose of 10 mg/kg had undesirable sedative effect (data not 
included). Thus a dose of 5 mg/kg b.w. was chosen for the further 
research and in the second model – the inflammation induced by the 
administration of Zymosan A only that dose was tested. 
The conducted tests clearly show that PSB-603 administered at a 
dose of 5 mg/kg b.w. ip significantly reduces inflammation in both the 
local and systemic inflammation model. This is an important finding 
considering the use of PSB-603, for several years now, as a selective 
adenosine A2B receptor antagonist reference compound. 
The inflammatory reaction occurs in two phases. Initially, TNF-α is 
released, which, along with cytokines such as IL-1β, IL-2, IL-6, IL-8, IL- 
15, and IFN-γ, belongs to the pro-inflammatory mediators. Immune 
system cells also produce free oxygen radicals and proteases and secrete 
lipid mediators (prostaglandins, leukotrienes). Subsequently, the 
increased activity of pro-inflammatory cytokines stimulates the syn-
thesis of anti-inflammatory cytokines such as soluble TNF receptors, IL-1 
and IL-4 antagonists, IL-10, IL-13, TNF-β. The next step is the post- 
inflammatory response [1]. There is a known correlation between CRP 
and inflammation, and therefore this protein has attracted wide atten-
tion as a non-specific marker used to evaluate and monitor the devel-
opment of infection and inflammation [36]. Thus, compounds with 
anti-inflammatory activity also lower plasma CRP levels [37–39]. 
Consequently, in our studies, the levels of CRP were quantified in 
mice plasma as well as the levels of TNF-α and IL-6 in both plasma and 
paws with induced inflammation. Moreover, the ROS levels were also 
assayed in the paws of mice with induced inflammation. 
In both models of inflammation, despite the fact that the differences 
Fig. 2. Anti-inflammatory effects of the compounds in the carrageenan-induced paw edema test. 
(A) Changes in paw volume in relations to the initial volume during 3 h (before carrageenan injection), Results are mean ± SEM, n = 8. Comparisons were performed 
by one-way ANOVA Dunnet’s post hoc. * - Significant against control mice administered with carrageenen; *p < 0.05, **p < 0.01, ***p < 0,001. (B) Concentration of 
C-reactive protein in plasma. Results are mean ± SEM, n = 8. Comparisons were performed by one-way ANOVA Tukey’s post hoc. * – Significant against control mice, 
^ – Significant against control mice administared with carrageenen; *p < 0.05, ^^^p < 0.001. 
Fig. 3. Effect of administration of PSB-603 or ketoprofen on TNF-α (A), IL-6 (B) and ROS (C) levels in paws in the carrageenan-induced paw edema test. 
Results are expressed as means ± SEM, n = 8. Comparisons were performed by one-way ANOVA Tukey’s post hoc. * – Significant against control mice; ^ – significant 
against control mice administared with carrageenen; *,^ p < 0.05, ^^p < 0.01, ***p < 0.001. 
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did not reach statistical significance, the level of CRP in plasma was 
visibly lowered by the administration of the tested adenosine A2B re-
ceptor antagonist PSB-603, which indicates its anti-inflammatory effect. 
In the model of local inflammation PSB-603 administration significantly 
reduced (similarly to ketoprofen) levels of both TNF-α and IL-6 in the 
paws of mice with induced inflammation. In the model of systemic 
inflammation administration of PSB-603 did not influence the plasma 
levels of TNF-α and IL-6. Contrarily, in the case of ketoprofen adminis-
tration, after zymosan A-induced peritonitis, plasma TNF-α and IL-6 
levels significantly increased. However, this is in line with literature 
reports. Non-steroidal anti-inflammatory drugs (NSAIDs) acting by 
inhibiting cyclooxygenase have long been known to augment TNF-α 
production in various in vitro and in vivo models including human vol-
unteers [40]. It has been shown that S-ketoprofen efficiently inhibited 
carrageenan-induced edema formation, but it could also amplify the 
LPS-induced production of inflammatory cytokines such as TNF-α and 
IL-1, in close correlation with its ability to inhibit prostaglandin syn-
thesis [41]. Upregulation of TNF-α production by inhibiting the negative 
feedback mechanism represented by PGE2 can increase the production 
of IL-6 [40] which in turn enhances the liver production of CRP [42]. In 
another study ketoprofen reduced inflammation by inhibiting cyclo-
oxygenase, but again, the compound paradoxically increased TNF-α 
levels in mice with surgically-induced lymphedema [26]. TNF-α is also a 
potent inducer of IL-1 and IL-6, and the kinetics of this process suggest 
that just the increase in the TNF-α levels might be an early step in the 
cytokine cascade [43]. 
PSB-603 not only significantly reduced the levels of inflammatory 
interleukins in paws with induced local inflammation, but what is more, 
and this should be especially emphasized, it reduced also levels of ROS. 
Oxidative stress is a hallmark of inflammation and is accompanied by 
a change in the cell redox balance with subsequent activation of redox- 
sensitive intracellular signalling pathways, which can be pro- or anti- 
inflammatory [50]. Adenosine inhibits the superoxide burst produced 
by the NADPH complex in response to activating agents including host- 
and bacterial-derived formylated peptides, a process that is essential for 
killing phagocytosed bacteria but that also promotes oxidant-induced 
tissue injury in inflammatory diseases such as asthma, arthritis, in-
flammatory bowel disease, and ischemia/reperfusion injury [44,45]. It 
is not known, however, whether this effect is mediated through the 
adenosine A2B receptor. There is one report in the literature that 
PSB-603 being a selective adenosine A2B receptor antagonist increased 
both mitochondrial oxygen consumption and intracellular ROS levels in 
in vitro tests [34]. However, in vitro tests performed in this study did not 
show a significant effect of the tested compound on oxidative processes. 
Fig. 4. Anti-inflammatory effect of PSB-603 or ketoprofen in model of zymosan-induced peritonitis in mice. 
(A) Neutrophil infiltration during zymosan-induced peritonitis in mice, (B) Concentration of C-reactive protein in plasma, (C) Concentration of TNF-α in plasma, (D) 
Concentration of IL-6 in plasma. Results are mean ± SEM, n = 8. Comparisons were performed by one-way ANOVA Tukey’s post hoc. * – Significant against control 
mice, ^ – Significant against control mice administared with zymosan. *,^p < 0.05, **,^^p < 0.01, ***p < 0.001. 
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The reduction of oxygen free radicals may depend on the dose/-
concentration used [46–48] since there are many reports confirming 
that an antioxidant used at too high dose/concentration facilitates the 
induction of free oxygen radicals [49]. What is more important, our ex 
vivo studies showed that ip administration of PSB-603 reduced the 
amount of ROS in the paws into which the inflammatory factor was 
injected. This anti-inflammatory effect of the PSB-603 compound might 
be associated with the blockade of adenosine A2B receptor, which in-
hibits the formation of ROS in the paws during the inflammatory reac-
tion (the compound was administered immediately before the 
inflammatory factor). However, those results might also be associated 
with an additional mechanism of anti-inflammatory action of PSB-603 
besides blocking the adenosine A2B receptor, which requires further 
study. 
Preliminary results described in this paper confirm the anti- 
inflammatory effect of the known highly potent and extraordinarily 
selective adenosine A2B receptor antagonist in acute models of local and 
systemic inflammation. They are promising and encourage us to perform 
further, expanded research using this interesting adenosine A2B receptor 
antagonist. 
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